Sort by

Send to

Choose Destination

Search results

Items: 4


Developing Infrastructure: Managing Patients With Cancer Undergoing CAR T-Cell Therapy

Halton E, Llerandi D, Diamonte C, Quintanilla H, Miale-Mayer D.

Clin J Oncol Nurs. 2017 Apr 1;21(2 Suppl):35-40. doi: 10.1188/17.CJON.2.35-40.


Phase behavior and interfacial properties of a switchable ethoxylated amine surfactant at high temperature and effects on CO2-in-water foams.

Chen Y, Elhag AS, Reddy PP, Chen H, Cui L, Worthen AJ, Ma K, Quintanilla H, Noguera JA, Hirasaki GJ, Nguyen QP, Biswal SL, Johnston KP.

J Colloid Interface Sci. 2016 May 15;470:80-91. doi: 10.1016/j.jcis.2016.02.028. Epub 2016 Feb 9.


Oral administration of surfactant protein-a reduces pathology in an experimental model of necrotizing enterocolitis.

Quintanilla HD, Liu Y, Fatheree NY, Atkins CL, Hashmi SS, Floros J, McCormack FX, Rhoads JM, Alcorn JL.

J Pediatr Gastroenterol Nutr. 2015 May;60(5):613-20. doi: 10.1097/MPG.0000000000000678.


Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He Q, Fink M, Shinglot H, Youssif M, Satter M, Wang Y, Hosey J, Quintanilla H, Halton E, Bernal Y, Bouhassira DC, Arcila ME, Gonen M, Roboz GJ, Maslak P, Douer D, Frattini MG, Giralt S, Sadelain M, Brentjens R.

Sci Transl Med. 2014 Feb 19;6(224):224ra25. doi: 10.1126/scitranslmed.3008226.

Supplemental Content

Loading ...
Support Center